北陆药业(300016.SZ)：获得碘美普尔注射液《药品注册证书》

Core Viewpoint - Beilu Pharmaceutical has received approval from the National Medical Products Administration for the iodine-based contrast agent, Iodixanol Injection, which is expected to enhance its product portfolio in the imaging agent market [1] Group 1: Product Details - Iodixanol Injection is developed by Italian company Bracco and is classified as a non-ionic monomer X-ray contrast agent [1] - The product exhibits superior physicochemical properties, having the lowest osmotic pressure and lower viscosity compared to similar non-ionic monomer X-ray contrast agents at the same concentration [1] - Iodixanol Injection is stable in its physicochemical properties and does not require the addition of chelating agents [1] Group 2: Indications - The indications for Iodixanol Injection include intravenous urography (for adults, including those with renal impairment or diabetes), CT imaging (trunk), conventional angiography, arterial DSA, cardiovascular imaging (for both adults and children), selective coronary angiography, interventional coronary angiography, fistula imaging, duct imaging, lacrimal duct imaging, and salivary duct imaging [1]